Artivion, Inc. is a medical device company that develops, manufactures and distributes technologies for cardiac and vascular surgeons, with a deliberate focus on the treatment of aortic diseases. Founded in 1984 and headquartered in Kennesaw, Georgia, the company employs more than 1,600 people worldwide and reaches customers in over 100 countries through its sales and distribution network, with offices across Europe, Asia and South America.
The company's portfolio spans four main areas: aortic stent grafts, surgical sealants, the On-X mechanical heart valve, and implantable cardiac and vascular human tissues. This work sits at the intersection of several technical disciplines, among them medical device development, manufacturing and distribution, mechanical heart valve technology, stent graft technology and surgical sealants. Manufacturing is carried out at three facilities, in Atlanta, Georgia; Austin, Texas; and Hechingen, Germany.
Artivion describes its mission as partnering with surgeons to restore patient health, working alongside leading cardiac and vascular surgeons to produce technologies intended to affect surgical outcomes. The business was rebranded from CryoLife to Artivion in January 2022, a change the company links to its concentrated strategic commitment to aortic-focused products.
